VivoSeq
Other

Acute Basilar Artery Occlusion

0

Pipeline Programs↗

3

Active Trials↗

0

Companies Involved↗

Acute Basilar Artery Occlusion is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

20/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Unknown status1 · 20%
Terminated1 · 20%

Clinical Trials

Trial Activity

Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion
Unknown status·FFirst Hospital of China Medical University·Phase 2·NCT05580822·520 enrolled
Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours
Recruiting·XXuanwu Hospital, Beijing·Phase 4·NCT07203625·316 enrolled
Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion
Recruiting·TThe First Affiliated Hospital of University of Science and Technology of China·Phase 3·NCT05827042·338 enrolled
Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT)
Terminated·GGeneral Hospital of Shenyang Military Region·Phase 3·NCT05657457·145 enrolled
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
Recruiting·—·N/A·NCT06101667·224 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)